Marilyn Kwan to Tamoxifen
This is a "connection" page, showing publications Marilyn Kwan has written about Tamoxifen.
Connection Strength
2.501
-
Endocrine therapy adherence and 10-year cardiometabolic risk in hormone receptor-positive breast cancer. JNCI Cancer Spectr. 2026 Nov 02; 10(6).
Score: 0.958
-
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
Score: 0.492
-
Effectiveness of bisphosphonate use and risk of contralateral breast cancer and recurrence in women with early-stage breast cancer treated with tamoxifen. Breast Cancer Res Treat. 2016 Apr; 156(2):379-89.
Score: 0.459
-
Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors. J Natl Cancer Inst. 2016 Mar; 108(3).
Score: 0.449
-
Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
Score: 0.078
-
Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
Score: 0.047
-
Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009 Nov; 118(2):395-405.
Score: 0.018